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Abstract
Random-effects meta-analyses are very commonly used in medical
statistics. Recent methodological developments include multivariate (mul-
tiple outcomes) and network (multiple treatments) meta-analysis. Here
we provide a new model and corresponding estimation procedure for mul-
tivariate network meta-analysis, so that multiple outcomes and treatments
can be included in a single analysis. Our new multivariate model is a di-
rect extension of a univariate model for network meta-analysis that has
recently been proposed. We allow two types of unknown variance pa-
rameters in our model, which represent between-study heterogeneity and
inconsistency. Inconsistency arises when different forms of direct and in-
direct evidence are not in agreement, even having taken between-study
heterogeneity into account. However the consistency assumption is often
assumed in practice and so we also explain how to fit a reduced model
which makes this assumption. Our estimation method extends several
other commonly used methods for meta-analysis, including the method
proposed by DerSimonian and Laird (1986). We investigate the use of
our proposed methods in the context of a real example.
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1 Introduction
Meta-analysis, the statistical process of pooling the results from separate stud-
ies, is commonly used in medical statistics and now requires little introduction.
The univariate random-effects model is often used for this purpose. This model
has recently been extended to the multivariate (multiple outcomes; Jackson et
al., 2011) and network (multiple treatments; Lu and Ades, 2004) meta-analysis
settings. In a network meta-analysis, more than two treatments are included
in the same analysis. The main advantage of network meta-analysis is that,
by using indirect information contained in the network, more precise and coher-
ent inference is possible, especially when direct evidence for particular treatment
comparisons is limited. Here we describe a new model that extends the random-
effects modelling framework to the multivariate network meta-analysis setting,
so that both multiple outcomes and multiple treatments may be included in the
same analysis.
Other multivariate extensions of univariate methods for network meta-analysis
have previously been proposed. For example, Achana et al. (2014) analyse mul-
tiple correlated outcomes in multi-arm studies in public health. Efthimiou et
al. (2014) propose a model for the joint modelling of odds ratios on multiple
endpoints. Efthimiou et al. (2015) develop another model that is a network ex-
tension of an alternative multivariate meta-analytic model that was originally
proposed by Riley et al. (2008). A network meta-analysis of multiple outcomes
with individual patient data has also been proposed by Hong et al. (2015) under
both contrast-based and arm-based parameterizations, and Hong et al. (2016)
develop a Bayesian framework for multivariate network meta-analysis. These
multivariate network meta-analysis models are based on the assumption of con-
sistency in the network, extending the approach introduced by Lu and Ades
(2004). In contrast to these previously developed methods, the method pro-
posed here relaxes the consistency assumption. This assumption is sometimes
found to be false across the entire network (Veroniki et al., 2013). We model the
inconsistency using a design-by-treatment interaction, so that different forms of
direct and indirect evidence may not agree, even after taking between-study
heterogeneity into account. However we assume that the design-by-interaction
terms follow normal distributions, and so conceptualise inconsistency as another
source of random variation. This allows us to achieve the dual aim of estimat-
ing meaningful treatment effects whilst also allowing for inconsistency in the
network.
Although we allow inconsistency in the network, we propose a relatively
simple model. Our preference for a simple model is because the between-study
covariance structure is typically hard to identify accurately in multivariate meta-
analyses (Jackson et al., 2011) and also because network meta-analysis datasets
are usually small (Nikolakopoulou et al., 2014). The new model that we propose
for multivariate network meta-analysis is a direct generalisation of the univariate
network meta-analysis model proposed by Jackson et al. (2016), which is a par-
ticular form of the design-by-treatment interaction model (Higgins et al., 2012).
In addition to proposing a new model for multivariate network meta-analysis, we
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also develop a corresponding new estimation method. This estimation method
is based on the method of moments and extends a wide variety of related meth-
ods. In particular, we extend the estimation method described by DerSimonian
and Laird (1986) by directly extending the matrix based extension of DerSi-
monian and Laird’s estimation method for multivariate meta-analysis (Chen
et al., 2012; Jackson et al., 2013). We adopt the usual two-stage approach to
meta-analysis, where the estimated study-specific treatment effects (including
the within-study covariance matrices) are computed in the first stage. We give
some information about how this first stage is performed but our focus is the
second stage, where the meta-analysis model is fitted.
The paper is set out as follows. In section 2, we briefly describe the univari-
ate model for network meta-analysis to motivate our new multivariate network
meta-analysis model in section 3. We present our new estimation method in
section 4 and we apply our methods to a real dataset in section 5. We conclude
with a short discussion in section 6.
2 A univariate network meta-analysis model
Here we describe our univariate modelling framework for network meta-analysis
(Jackson et al., 2016; Law et al., 2016). Without loss of generality, we take
treatment A as the reference treatment for the network meta-analysis. The
other treatments are B, C, etc. We take the design d as referring only to the set
of treatments compared in a study. For example, if the first design compares
treatments A and B only, then d = 1 refers to two-arm studies that compare
these two treatments. We define t to be the total number of treatments included
in the network, and td to be the number of treatments included in design d. We
define D to be the number of different designs, Nd to be the number of studies
of design d, and N =
D∑
d=1
Nd to be the total number of studies. We will use
the word ‘contrast’ to refer to a particular treatment comparison or effect in a
particular study, for example the ‘AB contrast’ in the first study.
We model the estimated relative treatment effects, rather than the average
outcomes in each arm, and so perform contrast based analyses. We define Ydi
to be the cd × 1 column vector of estimated relative treatment effects from the
ith study of design d, where cd = td − 1. We define nd = Ndcd to be the
total number of estimated treatment effects that design d contributes to the
analysis, and n =
D∑
d=1
nd to be the total number of estimated treatment effects
that contribute to the analysis. To specify the outcome data Ydi, we choose a
baseline treatment in each design d. The entries of Ydi are then the estimated
effects of the other cd treatments included in design d relative to this baseline
treatment. For example, if we take d = 2 to indicate the ‘CDE design’ then
c2 = 2. Taking C as the baseline treatment for this design, the two entries of
the Y2i vectors are the estimated relative effects of treatment D compared to C
and of treatment E compared to C. For example, the entries of the Ydi could
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be estimated log-odds ratios or mean differences.
We use normal approximations for the within-study distributions. We de-
fine Sdi to be the cd × cd within-study covariance matrix corresponding to Ydi.
We treat all Sdi as fixed and known in analysis. Ignoring the uncertainty in
the Sdi is acceptable provided that the studies are reasonably large and is con-
ventional in meta-analysis, but this approximation is motivated by pragmatic
considerations because this greatly simplifies the modelling. We do not impose
any constraints on the form of Sdi other than they must be valid covariance
matrices. The lead diagonal entries of the Sdi are within-study variances that
can be calculated using standard methods. Assuming that the studies are com-
posed of independent samples for each treatment, the other entries of the Sdi
are calculated as the variance of the average outcome (for example the log odds
or the sample mean) of the baseline treatment.
We define δAB1 , δ
AC
1 , · · · , δ
AZ
1 , where Z is the final treatment in the network,
to be treatment effects relative to the reference treatment A, and call them basic
parameters (Lu and Ades, 2006). We use the subscript 1 when defining the basic
parameters to emphasise that they are treatment effects for the first (and in this
section, only) outcome. We define c = t−1 to be the number of basic parameters
in the univariate setting. Treatment effects not involving A can be obtained as
linear combinations of the basic parameters and are referred to as functional
parameters (Lu and Ades, 2006). For example the average treatment effect of
treatment E to treatment C, δCE1 = δ
AE
1 − δ
AC
1 , is a functional parameter. We
define the c × 1 column vector δ = (δAB1 , δ
AC
1 , · · · , δ
AZ
1 )
T and design specific
cd× c design matrices Z(d). We use the subscript (d) in these design matrices to
emphasise that they apply to each individual study of design d; we reserve the
subscript d for design matrices that describe regression models for all outcome
data from this design. If the ith entry of the Ydi are estimated treatment effects
of treatment J relative to the reference treatment A then the ith row of Z(d)
contains a single nonzero entry: 1 in the (j−1)th column, where j is the position
of J in the alphabet. If instead the ith entry of the Ydi are estimated treatment
effects of treatment J relative to treatment K, K 6= A, then the ith row of Z(d)
contains two nonzero entries: 1 in the (j − 1)th column and -1 in the (k − 1)th
column.
Our univariate model for network meta-analysis is
Ydi = Z(d)δ +Θdi +Ωd + ǫdi (1)
where Θdi ∼ N(0, τ
2
βPcd), Ωd ∼ N(0, τ
2
ωPcd), ǫdi ∼ N(0,Sdi), all Θdi, Ωdi
and ǫdi are independent, and Pcd is the cd× cd matrix with ones on the leading
diagonal and halves elsewhere. We refer to τ2β and τ
2
ω as the between-study
variance, and the inconsistency variance, respectively. The term Θdi is a study-
by-treatment interaction term that models between-study heterogeneity. The
model Θdi ∼ N(0, τ
2
βPcd) implies that the heterogeneity variance is the same
for all contrasts for every study regardless of whether or not the comparison is
relative to the baseline treatment (Lu and Ades, 2004). Other simple choices
of Pcd , such as allowing the off-diagonal entries to differ from 0.5, violate this
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symmetry between treatments. For example, in the case d = 2 indicating the
CDE design, the between-study variances for the CD and CE effects in this
study are given by the two diagonal entries of τ2βPcd , which are both τ
2
β . The
between-study variance for the effect of E relative to D is (−1, 1)τ2βPcd(−1, 1)
T ,
which is also τ2β . The Ωd are design-by-treatment interaction terms that model
inconsistency in the network. The model Ωd ∼ N(0, τ
2
ωPcd) implies that the
inconsistency variance is the same for all contrasts for every design; other simple
choices of Pcd also violate this symmetry.
To describe all estimates from all studies, we stack the Ydi from the same
design to form the nd × 1 column vector Yd = (Y
T
d1, · · · ,Y
T
dNd
)T , and we then
stack these Yd to form the n× 1 column vector Y = (Y
T
1 , · · · ,Y
T
D )
T . Jackson
et al. (2016) then use three further matrices that we also define here because
they will be required to describe the estimation procedure that follows. The
matrix M1 is defined as a n × n square matrix where m1ij = 0 if the ith and
jth entries of Y , i, j = 1, · · ·n, are estimates from different studies; otherwise
m1ii = 1, and m1ij = 1/2 for i 6= j. The matrix M2 is defined as a n × n
square matrix where m2ij = 0 if the ith and jth entries of Y , i, j = 1, · · ·n, are
estimates from different designs; otherwise m2ij = 1 if the ith and jth entries
of Y are estimates of the same treatment comparison (for example, treatment
A compared to treatment B) and m2ij = 1/2 if these entries are estimates of
different treatment comparisons. The supplementary materials show a concrete
example showing how these two matrices are formed. Jackson et al. (2016)
also define a n × c univariate design matrix Z, where if the ith entry of Y is
an estimated treatment effect of treatment J relative to the reference treatment
A then the ith row of Z contains a single nonzero entry: 1 in the (j − 1)th
column, where j is the position of J in the alphabet. If instead the ith entry Y
is an estimated treatment effect of treatment J relative to treatment K, K 6= A,
then the ith row of Z contains two nonzero entries: 1 in the (j − 1)th column
and -1 in the (k − 1)th column. Defining Sd = diag(Sd1, · · · ,SdNd), and then
S = diag(S1, · · · ,SD), model (1) can be presented for the entire dataset as
Y ∼ N(Zδ, τ2βM1 + τ
2
ωM2 + S)
3 A multivariate network meta-analysis model
We now explain how to extend the univariate model in section 2 to the multi-
variate setting to handle multiple outcomes. We define p to be the number of
outcomes, and so the dimension of the network meta-analysis, so that we now
consider the case where p > 1. The Ydi are now pcd×1 column vectors, where the
Ydi contain cd column vectors of length p. For example, in a p = 5 dimensional
meta-analysis and continuing with the example where d = 2 indicates the CDE
design, we have c2 = 2. The Y2i are then 10×1 column vectors where, taking C
as the baseline treatment for this design, the first five entries of the Y2i are esti-
mated relative treatment effect of D compared to C and the second five entries
are the same estimate of E compared to C. We define the pc× 1 column vector
4
δ = (δAB1 , δ
AC
1 , · · · , δ
AZ
1 , δ
AB
2 , δ
AC
2 , · · · , δ
AZ
2 , · · · , δ
AB
p , δ
AC
p , · · · , δ
AZ
p )
T , so that
this vector contains the basic parameters for each outcome in turn. When p = 1
the vector δ reduces to its definition in the univariate setting, as given in section
2.
We define Σβ and Σω to be p × p unstructured covariance matrices that
are multivariate generalisations of τ2β and τ
2
ω. These two matrices contain the
between-study variances and covariances, and the inconsistency variances and
covariances, respectively, for all p outcomes. We refer to Σβ and Σω as the
between-study covariance matrix, and the inconsistency covariance matrix, re-
spectively. We continue to treat the within-study covariance matrices Sdi as if
fixed and known in analysis but these are now pcd × pcd matrices. The entries
of the Sdi matrices that describe the covariance of estimated treatment effects
for the same outcome can be obtained as in the univariate setting. However the
other entries of Sdi, that describe the covariance between treatment effects for
different outcomes, are harder to obtain in practice. A variety of strategies for
dealing with this difficulty have been proposed (Jackson et al., 2011; Wei and
Higgins, 2013).
3.1 The proposed multivariate model for network meta-
analysis
In the multivariate setting, to allow correlations between estimated treatment
effects for different outcomes, both within studies and designs, we propose that
model (1) is generalised to
Ydi =X(d)δ +Θdi +Ωd + ǫdi (2)
where X(d) = ((Ip ⊗Z(d)1)
T , · · · , (Ip ⊗Z(d)cd)
T )T , Z(d)i is the ith row of Z(d),
Θdi ∼ N(0,Pcd ⊗Σβ), Ωd ∼ N(0,Pcd ⊗ Σω) and ǫdi ∼ N(0,Sdi), where all
Θdi, Ωd and ǫdi are independent, and ⊗ is the Kronecker product. The random
Θdi and Ωd continue to model between-study heterogeneity, and inconsistency,
respectively. Recalling that δ contains the basic parameters for each outcome in
turn, the design matrices X(d) provide the correct linear combinations of basic
parameters to describe the mean of all estimated treatment effects in Ydi. Model
(2) reduces to model (1) in one dimension. The definition of Pcd means that Σβ
and Σω are the between-study covariance matrix, and inconsistency covariance
matrix, for all contrasts. We continue define Y as in the univariate setting,
where Y contains n column vectors of estimated treatment effects that are of
length p, so that Y is a np × 1 column vector in the multivariate setting. We
define the multivariate np×pc design matrixX = ((Ip⊗Z1)
T , · · · , (Ip⊗Zn)
T )T ,
where Zi is the ith row of Z. Model (2) can be presented for the entire dataset
as
Y ∼ N(Xδ,M1 ⊗Σβ +M2 ⊗Σω + S) (3)
where we continue to define S as in the univariate case. Matrices M1 and M2
are the same as in the univariate setting, and so continue to be n× n matrices.
Model (3) is a linear mixed model for network meta-analysis and is conceptually
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similar to other models of this type (Piepho et al., 2012). If Σω = 0 then all
Ωd = 0 and there is no inconsistency; we refer to this reduced model as the
‘consistent model’. If both Σβ = 0 and Σω = 0 then all studies estimate the
same effects to within-study sampling error and we refer to this model as the
‘common-effect and consistent model’.
Missing data (unobserved entries of Y) are common in applications as not
all studies may provide data for all outcomes and contrasts. When there are
missing outcome data, the model for the observed data is the marginal model
for the observed data implied by (3), where any rows of Y that contain missing
values are discarded. We will use a non-likelihood based approach for making
inferences and so assume any data are missing completely at random (Seaman
et al., 2013). We define the diagonal np×np missing indicator matrix R, where
Rii = 1 if Yi is observed, Rii = 0 if Yi is missing, and Rij = 0 if i 6= j.
4 Multivariate estimation: a new method of mo-
ments
Our estimation procedure is motivated by the univariate method proposed by
DerSimonian and Laird (1986). This was developed in the much simpler setting
where each study provides a single estimate Yi, and where the random-effects
model Yi ∼ N(δ, τ
2 + Si) is assumed. This estimation method for τ
2 uses the
Q statistic, where Q =
∑
S−1i (Yi − δˆ)
2 and δˆ =
∑
S−1i Yi/
∑
S−1i is the pooled
estimate under the common-effect model (τ2 = 0).
Now consider an alternative representation of this Q statistic. Taking Y =
(Y1, · · · , Yn)
T , S = diag(S1, · · · , Sn) and W = S
−1 means that Q = tr(W(Y−
Yˆ)(Y− Yˆ)T ), where Yˆ is obtained under the common-effect model. To obtain
a p × p matrix generalisation of Q for multivariate analyses, we replace the
trace operator with the block trace operator in this expression (Jackson et al.,
2013). The block trace operator is a generalisation of the trace that sums over
all n of the p× p matrices along the main block diagonal of an np× np matrix.
This produces a p× p matrix. In the absence of missing data we can write our
multivariate generalisation of the Q statistic, btr(W(Y − Yˆ)(Y − Yˆ)T ), as a
weighted sum of outer products of p× 1 vectors of residuals under the common-
effect and consistent model. Hence the distribution of btr(W(Y−Yˆ)(Y−Yˆ)T )
depends directly on the magnitudes of unknown variance components.
4.1 A Q matrix for multivariate network meta-analysis
We define a within-study precision matrix W corresponding to S. If there are
no missing outcome data in Y then we define W = S−1, where S is taken
from model (3). If there are missing data in Y then the entries of W that
correspond to observed data are obtained as the inverse of the corresponding
entries of the within-study covariance matrix of reduced dimension (equal to
that of the observed data) and the other entries of W are set to zero. For
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example, consider the case whereY is a 6×1 vector but only the second and fifth
entries are observed; this corresponds to much less outcome data than would be
used in practice but provides an especially simple example. Then we define Sr,
where the subscript r indicates a dimension reduction, as a 2× 2 matrix whose
entries are the within variances and covariances of the two observed entries of
Y. The 6 × 6 precision matrix W then has all zero entries in the first, third,
fourth and sixth rows and columns. However the remaining entries of W are
the entries of the 2 × 2 matrix S−1r , so that W22 = (S
−1
r )11, W25 = (S
−1
r )12,
W52 = (S
−1
r )21, and W55 = (S
−1
r )22. We define Yˆ to be the fitted value of
Y under the common-effect and consistent model (Σβ = Σω = 0), so that
Yˆ = HY where H = X(XTWX)−1XTW. We also define an asymmetric
np× np matrix (Jackson et al., 2013)
Q =W{R(Y − Yˆ)}{R(Y − Yˆ)}T =W(Y − Yˆ)(Y − Yˆ)TR (4)
Our definitions ofW andRmean thatWR =W, which results in the simplified
version of Q in (4). From the first form given in (4), we have that the residuals
Y−Yˆ are pre-multiplied by R, so that any residuals that correspond to missing
outcome data do not contribute to Q. Furthermore missing outcome data do
not contribute to Yˆ because they have no weight under the common-effect
and consistent model. Hence we can impute missing outcome data with any
finite value without changing the value of Q. This is merely a convenient way
to handle missing data numerically and has no implications for the statistical
modelling.
4.2 Design specific Q matrices for multivariate network
meta-analysis
In order to identify the full model, we will require design-specific versions of Q
that only use data from a particular design. As in the univariate setting, we stack
the outcome data from design d to form the vector Yd = (Y
T
d1, · · · ,Y
T
dNd
)T .
In the multivariate setting the vector Yd contains nd estimated effects each
of length p, so that Yd is now a pnd × 1 column vector. We define the design
specific nd×nd matrixM
d
1
, wheremd1ij = 0 if the ith and jth estimated effect (of
length p) in Yd, i, j = 1, · · · , nd, are from separate studies; otherwise m
d
1ii = 1
and md1ij = 1/2 for i 6= j. We define the pnd × pcd design matrix Xd which is
obtained by stacking identity matrices of dimension pcd, where we include one
such identity matrix for each study of design d. Hence Xd = 1Nd ⊗ Ipcd , where
1Nd is the Nd × 1 column vector where every entry is one. We also define the
pcd × 1 column vector βd =X(d)δ +Ωd.
An identifiable design-specific marginal model for outcome data from design
d only, that is implied by model (2), is
Yd ∼ N(Xdβd,M
d
1
⊗Σβ + Sd) (5)
where Sd = diag(Sd1, · · · ,SdNd). We can also calculate design specific versions
of (4) where we calculate all quantities, including the fitted values, using just
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the data from studies of design d. We define these pnd × pnd design specific
matrices as
Qd =Wd(Yd − Yˆd)(Yd − Yˆd)
TRd (6)
whereWd, Rd and Yˆd in (6) are defined in the same way asW, R and Yˆ in (4)
but where only data from design d are used. Hence Rd and Wd are the missing
indicator matrix, and the within-study precision matrix, ofYd, respectively. We
compute Yˆd = HdYd where Hd = Xd(X
T
dWdXd)
−1XTdWd. When computing
Hd we take the matrix inverse to be the Moore-Penrose pseudoinverse. This is
so that any design-specific regression corresponding to this hat matrix that is
not fully identifiable (due to missing outcome data) can still contribute to the
estimation. We use model (5) to derive the properties of Qd in equation (6).
4.3 The estimating equations
We base our estimation on the two p×p matrices btr(Q) and
D∑
d=1
btr(Qd), where
Q and Qd are given in (4) and (6), respectively. Specifically, we match these
quantities to their expectations to estimate the unknown variance parameters
using the method of moments.
4.3.1 Evaluating E[btr(Q)] and deriving the first estimating equation
We define A = (Inp −H)
TW and B = (Inp −H)
TR, which are known np×np
matrices. We also divide the matrices A and B into n2 blocks of p×p matrices,
and writeAi,j and Bi,j , i, j = 1, · · ·n, to mean the ith by jth blocks of A and B
respectively. Hence Ai,j and Bi,j are both p×p matrices. In the supplementary
materials we show that
E[btr(Q)] =
n∑
i=1
n∑
j=1
n∑
k=1
m1ijAk,iΣβBj,k+
n∑
i=1
n∑
j=1
n∑
k=1
m2ijAk,iΣωBj,k + btr(B).
We apply the vec(·) operator to both sides of the previous equation and use the
identity vec(AXB) = (BT ⊗ A)vec(X) (see Henderson and Searle, 1981), to
obtain
vec(E[btr(Q)]) = Cvec(Σβ) +Dvec(Σω) +E (7)
where
C =
n∑
i=1
n∑
j=1
n∑
k=1
m1ijB
T
j,k ⊗Ak,i
D =
n∑
i=1
n∑
j=1
n∑
k=1
m2ijB
T
j,k ⊗Ak,i
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and
E = vec(btr(B)).
Upon substituting E[btr(Q)] = btr(Q), Σβ = Σˆβ and Σω = Σˆω in equation (7),
the method of moments gives one estimating equation in the vectorised form of
two unknown covariance matrices.
4.3.2 Evaluating E[btr(Qd)] and deriving the second estimating equa-
tion
Model (5) depends upon one unknown covariance matrix, Σβ . The intuition is
that, upon using all D of the Qd matrices in (6) and the method of moments
to estimate Σβ, we will then be able to estimate the other unknown covariance
matrix Σω using the first estimating equation. We define design specific Ad =
(Ipnd − Hd)
TWd and Bd = (Ipnd − Hd)
TRd , where Ad and Bd are known
pnd×pnd matrices. We also divide the matrices A and B into n
2
d blocks of p×p
matrices, and write Ad,i,j and Bd,i,j , i, j = 1, · · · , nd, to mean the ith by jth
blocks of Ad and Bd respectively. In the supplementary materials we show that
vec
(
E[
D∑
d=1
btr(Qd)]
)
=
(
D∑
d=1
Cd
)
vec(Σβ) +
D∑
d=1
Ed (8)
where
Cd =
nd∑
i=1
nd∑
j=1
nd∑
k=1
md1ijB
T
d,j,k ⊗Ad,k,i
and
Ed = vec(btr(Bd)).
Upon substituting E[
D∑
d=1
btr(Qd)] =
D∑
d=1
btr(Qd) and Σβ = Σˆβ in (8), we obtain
a second estimating equation from the method of moments.
4.4 Solving the estimating equations and performing in-
ference
We solve the estimating equation resulting from (8) for vec(Σˆβ) and substi-
tute this estimate into the estimating equation resulting from (7) and solve for
vec(Σˆω).
4.4.1 Estimating Σβ under the consistent model
Some applied analysts may prefer to assume the consistent model (Σω = 0).
As in the univariate case (Jackson et al., 2016), we have two possible ways of
estimating Σβ under the consistent model: we can use the estimating equation
resulting from (7) with Σω = 0 or the estimating equation resulting from (8) as
in the full model. Also as in the univariate case, we suggest the former option
because it uses the information made by assuming consistency when estimating
Σβ. However this first option is valid only under the consistent model.
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4.4.2 ‘Truncating’ the estimates of the unknown covariance matrices
so that they are symmetric and positive semi-definite
As in the univariate case, there is the problem that the point estimates of the
two unknown covariance matrices are not necessarily positive semi-definite. The
method of moments does not even initially enforce the constraint that the point
estimates of the unknown covariance matrices are symmetrical (Chen et al.,
2012; Jackson et al., 2013). We produce symmetric estimators corresponding to
an estimated covariance matrix of Σˆ as (ΣˆT + Σˆ)/2 (Chen et al., 2012; Jackson
et al., 2013). This also corresponds to taking the average of estimates that result
from our Q and Qd matrices and their transposes (Jackson et al., 2013). We
then write these symmetric estimators in terms of their spectral decomposition
(Chen et al., 2012; Jackson et al., 2013) and truncate any negative eigenvalues to
zero to provide the final symmetric positive semi-definite estimated covariance
matrices. Specifically, we define the truncated estimate corresponding to the
symmetrical Σˆ as Σˆ+ =
p∑
i=1
max(0, λi)eie
T
i , where λi is the ith eigenvalue of
the symmetric Σˆ and ei is the corresponding normalised eigenvector.
4.4.3 Inference for δ
Inference for δ then proceeds as a weighted regression where all weights are
treated as fixed and known. Writing Vˆ as the estimated variance of Y in (3),
in the absence of missing outcome data we have δˆ = (XT Vˆ−1X)−1XT Vˆ−1Y
where Var(δˆ) = (XT Vˆ−1X)−1. In the presence of missing data we can, under
our missing completely at random assumption, apply these standard formulae
for weighted regression to the observed outcomes. Alternatively and equiva-
lently, we can impute the missing outcome data in Y with an arbitrary value
and replace Vˆ−1 with the precision matrix corresponding to Vˆ, calculated in
the way explained for S in section 4.1 (Jackson et al., 2011). Approximate con-
fidence intervals and hypothesis tests for all basic parameters for all outcomes
then immediately follow by taking δˆ to be approximately normally distributed.
Inferences for functional parameters follow by taking appropriate linear combi-
nations of δˆ.
4.5 Special cases of the estimation procedure
In the supplementary materials we show that the proposed method reduces to
two previous methods in special cases. If all studies are two arm studies and
consistency is assumed then the proposed method reduces to the matrix based
method for multivariate meta-regression (Jackson et al., 2013). The proposed
multivariate method reduces to the univariate DerSimonian and Laird method
for network meta-analysis (Jackson et al., 2016) when p = 1.
10
4.6 Model identification
If the necessary standard matrix inversions resulting from the estimating equa-
tions from (7) and (8) cannot be performed then both unknown variance compo-
nents cannot be identified using the proposed method. A minimum requirement
for any multivariate modelling is that the common-effect and consistent model
must be identifiable. This means that there must be some information (direct or
indirect) about each basic parameter for all outcomes. Two or more studies of
the same design must provide data for all possible pairs of outcomes to identify
Σβ. Two or more studies of different designs must provide data for all possi-
ble pairs of outcomes to identify Σω. If these conditions are satisfied then the
model will be identifiable. In situations where our model is not identifiable we
suggest that simpler models should be considered instead. Possible strategies
for this include considering models of lower dimension or the consistent model.
In practice it is highly desirable to have more than the minimum amount of
replication required, both within and between designs, so that the model is well
identified. We make some pragmatic decisions in the next section for our ex-
ample to provide sufficient replication within designs, in order to estimate Σβ
with reasonable precision.
5 Example
The methodology developed in this paper is now applied to an illustrative ex-
ample in relapsing remitting multiple sclerosis (RRMS). Multiple sclerosis (MS)
is an inflammatory disease of the brain and spinal cord and RRMS is a common
type of MS. The effectiveness of a new treatment is typically measured to assess
its impact on relapse rate and odds of disease progression. Magnetic Resonance
Imaging (MRI) allows measurement of the number of new or enlarging lesions
in the brain. Three outcomes are included in our analyses, so that p = 3 in the
full three dimensional network meta-analysis. These three outcomes are: (1)
the log rate ratio of new or enlarging MRI lesions; (2) the log annualised relapse
rate ratio; and (3) log disability progression odds ratio. Relapse is defined as
appearance of new, worsening or recurrence of neurological symptoms that can
be attributable to MS, accompanied by an increase of a score on the Expanded
Disability Status Scale (EDSS) and also functional-systems score(s), lasting at
least 24 hours, preceded by neurologic stability for at least 30 days. Disability
progression is defined as an increase in EDSS score that was sustained for 12
weeks, with an absence of relapse at the time of assessment. Negative basic
parameters indicate that treatments B-F are beneficial compared to treatment
A throughout.
Data in this illustrative example were obtained from ten randomised con-
trolled trials of six treatment options (coded in the network data as treatments
A to F); placebo (A), interferon beta-1b (B), interferon beta-1a (C), glatiramer
(D), and two doses of fingolimod; 0.5mg (E) and 1.25mg (F). Three of the fin-
golimod trials were three-arm (two doses and a control) and are included as
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three-arm studies. Three trials of interferon beta (one 1a and two 1b) were
three-arm (also two doses and a control), and these were included as separate
two-arm trials (each dose against the control, with the number of participants in
each control arm halved). This ignores the differences in doses of interferon beta
and was a pragmatic decision to help provide an identifiable network. Briefly,
in this example there is very little replication within designs, so that identifying
Σβ well is very difficult without making pragmatic decisions such as this. Sor-
mani et al. (2010) also treat these particular studies as two separate studies in
this way, which helps them to identify their meta-regression models. Treating
these three studies as separate two-arm trials means that the data are analysed
as being from thirteen studies and a summary of the resulting data structure
is shown in Table 1. There are eight different designs in Table 1 and so there
is relatively little replication within designs, even when including three of the
three-arm studies as separate two arm studies. See Bujkiewicz et al. (2016) for
further details of these data. Figure 1 provides network diagrams that show
the number of comparisons between each pair of treatments on the edges. In
these diagrams the three arm studies (Table 1) are taken to contribute three
comparisons, for example the CEF study contributes CE, CF and EF compar-
isons. Two estimates of treatment effect from this study contribute to analyses
however because C is taken as the baseline; the study’s estimated EF treat-
ment effect contains no additional information once its CE and CF contrasts
are included in the analysis.
Table 1: Summary of the relapsing remitting multiple sclerosis dataset.
Study Design Outcomes
IFNB SG (1) AB All three outcomes measured
IFNB SG (2) AB All three outcomes measured
Jacobs/Simon AC All three outcomes measured
PRISMS (1) AC All three outcomes measured
PRISMS (2) AC All three outcomes measured
Johnson AD Relapse rate and disability progression only
Durelli BC Relapse rate and disability progression only
O’Connor (1) BD Relapse rate and disability progression only
O’Connor (2) BD Relapse rate and disability progression only
Mikol CD All three outcomes measured
FREEDOMS 1 AEF All three outcomes measured
FREEDOMS 2 AEF All three outcomes measured
TRANSFORMS CEF All three outcomes measured
Table 2 shows the estimates of the basic parameters (treatment effects rel-
ative to the reference treatment, placebo) obtained from univariate network
meta-analyses, bivariate analyses for all three combinations of pairs of out-
comes and the trivariate analysis. The results are similar across all analyses,
and conclusions from univariate and multivariate analyses are the same. This
is disappointing because multivariate analyses have not resulted in more precise
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Figure 1: Network diagram for RRMS dataset. A – placebo, B – interferon
beta-1b, C – interferon beta-1a, D – glatiramer, E – fingolimod 0.5mg, F –
fingolimod 1.25mg. Left-hand-side network corresponds to studies reporting the
log annualised relapse rate ratio and log disability progression odds ratio (y2 and
y3) for which data are complete. The right-hand-side network corresponds to
studies reporting the log rate ratio of new or enlarging MRI lesions (y1 which
is not reported in four studies). The numbers shown on the network edges are
the number of direct comparisons of each pair of treatments; the absence of an
edge indicates that there is no direct comparison. Three of the thirteen studies
are three arm trials which are each taken to provide three direct comparisons
(a direct comparison between each treatment pair). Hence there are 19 direct
comparisons in the left-hand-side network where there is no missing data.
D
B C
A E
F
2 1
1
32
2
1
1
1
2 3
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B C
A E
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32
2
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Table 2: Treatment effect estimates of each treatment relative to the reference treatment A (placebo).
model estimate (se)
AB AC AD AE AF
MRI (y1)
univariate (y1) -0.95 (0.39) -1.00 (0.21) -0.68 (0.50) -1.38 (0.26) -1.52 (0.26)
bivariate (y1, y2) -0.94 (0.39) -1.00 (0.21) -0.68 (0.50) -1.39 (0.26) -1.53 (0.26)
bivariate (y1, y3) -0.96 (0.39) -0.98 (0.22) -0.66 (0.50) -1.38 (0.26) -1.51 (0.26)
trivariate (y1, y2, y3) -0.96 (0.39) -0.97 (0.22) -0.67 (0.50) -1.38 (0.26) -1.51 (0.26)
Relapse rate (y2)
univariate (y2) -0.35 (0.10) -0.25 (0.09) -0.34 (0.11) -0.81 (0.12) -0.78 (0.12)
bivariate (y1, y2) -0.35 (0.10) -0.25 (0.09) -0.34 (0.11) -0.81 (0.12) -0.78 (0.12)
bivariate (y2, y3) -0.36 (0.11) -0.23 (0.10) -0.33 (0.12) -0.80 (0.13) -0.77 (0.13)
trivariate (y1, y2, y3) -0.36 (0.11) -0.23 (0.10) -0.33 (0.12) -0.80 (0.13) -0.77 (0.13)
Disability progression (y3)
univariate (y3) -0.46 (0.25) -0.11 (0.21) -0.42 (0.25) -0.33 (0.25) -0.37 (0.24)
bivariate (y2, y3) -0.47 (0.25) -0.10 (0.21) -0.43 (0.25) -0.37 (0.25) -0.37 (0.25)
bivariate (y1, y3) -0.46 (0.25) -0.11 (0.21) -0.42 (0.25) -0.34 (0.25) -0.38 (0.25)
trivariate (y1, y2, y3) -0.47 (0.25) -0.10 (0.21) -0.43 (0.25) -0.37 (0.25) -0.37 (0.25)
1
4
Table 3: Inconsistency and heterogeneity covariance matrices estimates.
model Σω11 Σω12 Σω13 Σω22 Σω23 Σω33
univariate (y1) 0.0000
univariate (y2) 0.0115
univariate (y3) 0.0713
bivariate (y1, y2) 0.0002 0.0017 0.0125
bivariate (y1, y3) 0.0018 0.0116 0.0741
bivariate (y2, y3) 0.0161 0.0344 0.0735
trivariate (y1, y2, y3) 0.0027 0.0066 0.0143 0.0161 0.0349 0.0756
Σβ11 Σβ12 Σβ13 Σβ22 Σβ23 Σβ33
univariate (y1) 0.1508
univariate (y2) 0.0043
univariate (y3) 0.0000
bivariate (y1, y2) 0.1523 -0.0110 0.0047
bivariate (y1, y3) 0.1526 -0.0191 0.0024
bivariate (y2, y3) 0.0061 0.0015 0.0004
trivariate (y1, y2, y3) 0.1538 -0.0116 -0.0195 0.0059 0.0024 0.0027
inference. The entries of Σˆβ and Σˆω are shown in Table 3. The positive esti-
mates obtained for the unknown variance components suggest that this example
exhibits some between-study heterogeneity and inconsistency. In order to assess
the impact of the unknown variance components, we also fitted the consistent
model and the common-effect and consistent model (results not shown) using
all three outcomes (p = 3). On average, the standard errors of the fifteen ba-
sic parameters from the full model are 35% greater (range: 13% to 84%) than
those from the consistent model, which in turn are 58% (range: 8% to 128%)
greater than those from the common-effect and consistent model. Both the
between-study heterogeneity and inconsistency have notable impact.
The multivariate analysis adds to the univariate analyses in two main ways.
Firstly, the finding that the multivariate analysis is in good agreement with the
univariate analyses is a particularly important finding for treatment effects on
MRI where a substantial proportion of data were missing. It has been demon-
strated by Kirkham et al. (2012) that a multivariate approach to meta-analysis
can help obtain more accurate estimates in the presence of outcome reporting
bias. Hence the multivariate analysis reduces concerns that this univariate anal-
ysis is affected by reporting bias. Secondly joint inferences for all three outcomes
are possible under the multivariate model. For example, and as we might antic-
ipate, in our example the estimated log annualised relapse rate ratios and log
disability progression odds ratios are highly positively correlated; from Var(δˆ) in
our three dimensional multivariate meta-analysis, the correlations between the
five pairs of estimated basic parameters for these two outcomes are all between
0.63 and 0.75. Medical decision making based jointly on these two outcomes
should take this high positive correlation into account, and this is only possi-
ble by using a multivariate approach. For example, a formal decision analysis
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involving these two outcomes should be based on their joint distribution rather
than their two marginal distributions.
6 Discussion
We have proposed a new model for dealing with both multiple treatment con-
trasts and multiple outcomes, to provide a framework for conducting multi-
variate network meta-analysis. By using a matrix-based method of moments
estimator, our methodology naturally builds on previous work (such as the
well-known DerSimonian and Laird approach) and is computationally very fast,
relative to other potential estimation approaches such as REML or MCMC; this
is especially the case in very high dimensions and so our methodology is partic-
ularly advantageous for ambitious analyses of this type. The main disadvantage
is that, as a necessary consequence of its semi-parametric nature, the method
of moments is not based on sufficient statistics and so is not fully efficient. The
loss in efficiency relative to maximum likelihood estimation awaits investigation
but we anticipate that this will be less serious for inferences about the average
effects than the unknown variance components. Furthermore the within-study
normal approximations used in our model are not necessarily very accurate even
in moderately sized studies.
Since our analysis uses a general design matrix, the modelling may easily
be extended by adding study level covariates to describe and fit multivariate
network meta-regressions. In the network meta-analysis setting these regressions
have the potential to explain the reasons for inconsistency and model multiple
dose level responses. Our method of moments estimation can be combined with
approaches that ‘inflate’ confidence intervals from a frequentist random effects
meta-analysis (Hartung and Knapp, 2001; Jackson and Riley, 2014).
In conclusion, we have developed a new model and estimation method for
multivariate network meta-analysis, which can describe multiple treatments and
multiple correlated outcomes.
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Supplementary Materials
Multivariate estimation
An important result
In order to evaluate the expectations required, we will need to be able to com-
pute expressions of the form btr(A(M ⊗ Σ)B), where A and B are np × np
matrices, M is an n × n matrix and Σ is a p × p matrix. We continue to use
the notation Ai,j to denote the ith by jth block of A, where these blocks are
p× p matrices. For any three np× np matrices A, B and C, we have
(ACB)k,l =
n∑
i=1
n∑
j=1
Ak,iCi,jBj,l
This is just the law of matrix multiplication applied to blocks. Then taking
C =M⊗Σ so that from the definition of the Kronecker product, Ci,j = mijΣ,
we have
(A(M ⊗Σ)B)k,l =
n∑
i=1
n∑
j=1
mijAk,iΣBj,l
To obtain the block trace, we sum the matrices along the main diagonal. Hence
to obtain the block trace we take l = k to obtain the matrices along the main
diagonal and sum over k so obtain
btr(A(M⊗Σ)B) =
n∑
i=1
n∑
j=1
n∑
k=1
mijAk,iΣBj,k (9)
The use of equation (9), with the appropriate matrices, almost immediately
results in the expected values required in section 4.
The estimating equations
In this section we prove the results given in section 4 of the main paper. We
do not redefine all quantities or give the size of all matrices and vectors, see the
main paper for these details. As in the univariate approach of Jackson et al.
(2016), we will base our estimation on the two quantities btr(Q) and
D∑
d=1
btr(Qd)
where D is the number of different designs. We match these quantities to their
expectations to estimate the unknown variance parameters. We therefore need
to evaluate E[btr(Q)] and E[btr(Qd)].
Evaluating E[btr(Q)] and deriving the first estimating equation
As in Jackson et al. (2013), by direct calculation we have that WHW−1 = HT
and ((Inp −H)
T )2 = (Inp −H)
T ; if W is not invertible because outcome data
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are missing then we can justify the use of the identity WHW−1 = HT and
the expectation that follows in the limit, where the precision p attributed to
missing data tends towards zero from above, p → 0+ (Jackson et al., 2013).
Furthermore we can use the identity W = S−1 in this limit. We also have that
Y − Yˆ = (Inp −H)Y and E[Y − Yˆ] = 0. Hence from the definition of Q we
have E[Q] = WVar[Y − Yˆ]R. From these results, taking the variance of Y
from model (3) of the main paper, we can evaluate
E[Q] = A(M1 ⊗Σβ +M2 ⊗Σω)B+B
where
A = (Inp −H)
TW
and
B = (Inp −H)
TR
Here A and B are known np×np matrices. For estimation purposes we require
E[btr(Q)] = btr(E[Q]). We write Ai,j and Bi,j to mean the ith by jth blocks
of A and B respectively, so that Ai,j and Bi,j are both p× p matrices. Then,
using (9), we have
E[btr(Q)] =
n∑
i=1
n∑
j=1
n∑
k=1
m1ijAk,iΣβBj,k+
n∑
i=1
n∑
j=1
n∑
k=1
m2ijAk,iΣωBj,k + btr(B)
Evaluating E[btr(Qd)] and deriving the second estimating equation
Then we follow very similar, but much simpler, arguments as in the previous
section to derive the result that we require. We define design specific hat ma-
trices
Hd = Xd(X
T
dWdXd)
−1XTdWd (10)
and also design specific pnd × pnd A and B matrices
Ad = (Ipnd −Hd)
TWd
and
Bd = (Ipnd −Hd)
TRd
In equation (10) we take the matrix inverse to be the Moore-Penrose pseudoin-
verse. This is because, in the presence of missing outcome data, the design-
specific regression corresponding to this hat matrix may not be identifiable (for
example, if studies of a particular design do not provide data for one or more
of the outcomes). In such instances this design may still provide information
about some of the unknown between-study variance components and so it is
not desirable to exclude the design from this part of the estimation procedure.
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By computing (10) using this pseudoinverse we obtain a suitable hat matrix
(Searle, 1971; page 221, his equations 126 and 127). Furthermore all the nec-
essary properties of the hat matrix are retained when using the pseudoinverse
when computing (10) and we retain unbiased fitted values (Searle, 1971; page
181).
Following a simpler version of the arguments in the previous section and the
main paper, taking the variance of Yd from model (5) of the main paper, and
upon applying the vec operator, we obtain
vec(E[btr(Qd)]) = Cdvec(Σβ) +Ed (11)
where
Cd =
nd∑
i=1
nd∑
j=1
nd∑
k=1
md1ijB
T
d,j,k ⊗Ad,k,i
and
Ed = vec(btr(Bd))
We then sum equation (11) across all designs in order to obtain
vec
(
E[
D∑
d=1
btr(Qd)]
)
=
(
D∑
d=1
Cd
)
vec(Σβ) +
D∑
d=1
Ed
Special cases of the estimation procedure (an extended ver-
sion of section 4.5)
The proposed method reduces to two previous methods in special cases. If all
studies are two arm studies (and so provide a single contrast) and consistency
is assumed then the proposed method reduces to the matrix based method for
multivariate meta-regression (Jackson et al., 2013). This is because we then
have Σω = 0, so that the second triple sum in our expression for E[btr(Q)] is
zero; furthermore the first triple summation in this expression can be reduced to
a double summation, because M1 is an identity matrix for multivariate meta-
regression (Jackson et al., 2013; their equation A.1.).
Furthermore the proposed multivariate method also reduces to the univariate
DerSimonian and Laird method for network meta-analysis (Jackson et al., 2016)
when p = 1. This is because, in one dimension, the Q matrices all reduce to the
Q random scalars used in the estimation procedure suggested by Jackson et al.
(2016). This can be shown by replacing the block trace operator with the more
familiar trace of a matrix (btr is the trace when p = 1) in the definition of the
Q matrices and using the identity tr(AB) = tr(BA). These two special cases
are in turn generalisations of methods such as that proposed by DerSimonian
and Laird (1986).
There is however one caveat when stating that the new multivariate method
reduces to the univariate method proposed by (Jackson et al., 2016) when p = 1.
This is because the account of Jackson et al. (2016) does not mention the
possibility of missing outcome data and so we have implicitly taken all data to
be observed in the argument used in the previous paragraph.
22
Example of matrices M1 and M2
We provide a concrete example of matricesM1 andM2, in order to clarify how
they are computed. We take such an example from Law et al. (2016) which
comprises thirteen studies with the following study designs: AB, BC, BC, BC,
BC, BC, BD, BD, CD, CD, ABD, BCD, BCD. This is the same type of network
as used in the simulation study below. The two matrices for this example are
given explicitly below, where we can see that these matrices contain blocks that
are comprised of blocks of Pcd , where in M1 the blocks are formed by studies
and in M2 the blocks are formed by designs.
M1 =


1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 1 12 0 0 0 0
0 0 0 0 0 0 0 0 0 0 12 1 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 1 12 0 0
0 0 0 0 0 0 0 0 0 0 0 0 12 1 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 12
0 0 0 0 0 0 0 0 0 0 0 0 0 0 12 1


23
M2 =


1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 1 12 0 0 0 0
0 0 0 0 0 0 0 0 0 0 12 1 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 1 12 1
1
2
0 0 0 0 0 0 0 0 0 0 0 0 12 1
1
2 1
0 0 0 0 0 0 0 0 0 0 0 0 1 12 1
1
2
0 0 0 0 0 0 0 0 0 0 0 0 12 1
1
2 1

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